ITRM Iterum Therapeutics plc: institutional ownership and insider trading
Over the last 12 months insiders bought $2.22K and sold $0 on the open market.
ITRM revenue and earnings
- Quarter ended Sep 30, 2025: revenue $390K, net income −$8.98M, EPS -0.20
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.51M, EPS -0.16
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.89M, EPS -0.14
- Quarter ended Dec 31, 2024: revenue n/a, net income −$6.58M, EPS -0.20
Recent ITRM insider trades
- Nov 18, 2025: Dunne Michael W. bought 6,000 shares ($2.22K)
- Aug 8, 2025: Dunne Michael W. bought 15,000 shares ($10.8K)
Are insiders buying or selling ITRM?
Over the last 12 months insiders bought $2.22K and sold $0 of Iterum Therapeutics plc stock on the open market (SEC Form 4).
What was ITRM's revenue last quarter?
Iterum Therapeutics plc reported revenue of $390K for the quarter ended September 30, 2025, with net income of −$8.98M.